Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
To determine feasibility of recruitment and tolerability of treatment with
sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who
have stage B heart failure.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Virginia Commonwealth University
Treatments:
Sacubitril and valsartan sodium hydrate drug combination Valsartan